Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Childhood-Onset Schizophrenia
NCT01712646Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2012
- Primary completion
- Jun 2016
- Countries
- 1
- Sponsor
- National Institute of Mental Health
- Drugs
- oxytocin nasal spray
- Conditions
- schizophrenia
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in schizophrenia, sponsored by National Institute of Mental Health. Primary endpoints: Safety of intranasal oxytocin at 4 weeks and Positive and Negative Syndrome Scale at 4 weeks. Started Oct 2012; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Children aged 10 and older with childhood-onset schizophrenia who remain symptomatic despite stable medication for at least one month.
04
Endpoints
Primary
Safety of intranasal oxytocin
Positive and Negative Syndrome Scale
Beyond the preview
Go deeper on NCT01712646.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712646.